Hepatitis C Therapy

InterMune initiates phase Ia trial for ITMN-191 in collaboration with Roche

Published in Hepatitis Weekly, January 15th, 2007

InterMune, Inc., (ITMN) announced that the company and its partner Roche have received approval of the European Clinical Trial Authorization for ITMN-191, the NS3/4A protease inhibitor, and have initiated a phase Ia clinical trial evaluating ITMN-191 for the treatment of chronic hepatitis C virus (HCV) infection.

The phase Ia trial will assess safety, tolerability, pharmacokinetics, and food affect in a double-blind, placebo-controlled, single-ascending-dose study. The study is being conducted at 1 clinical trial site in Europe and will enroll approximately 74 healthy volunteers. InterMune expects to dose the first patient with ITMN-191 sometime in early January...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2007-01-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry